AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1-32. (canceled).

33. (currently amended): An expression vector,

comprising: (a) a first coding region encoding a peptidyl-prolyl cis-trans isomerase (PPIase) having molecular chaperone activity, and

(b) a region having at least one restriction enzyme site in which a second coding region encoding a desired protein can be inserted,

wherein the PPIase is archaebacterial FKBP-type PPIase.

34. (previously presented): The expression vector according to claim 33,

wherein the first coding region is operatively linked to a promoter, and the restriction enzyme site is in the same reading frame as the first coding region, and is downstream of the first coding region.

35. (currently amended): The expression vector according to claim 33 ,

which has a region between the first coding region and the region having at least one restriction enzyme site in which a second coding region can be inserted, wherein the region encodes a protease digestion site in the same reading frame as (a) and (b)~~encoding a protease digestion site in the same reading frame as the first and second coding regions~~.

36. (previously presented): An expression vector,

wherein a second coding region encoding a desired protein is inserted into the expression vector according to claim 33.

37. (canceled): ~~The expression vector according to claim 33 ,~~

~~wherein the PPIase having molecular chaperone activity is FKBP-type PPIase~~.

38. (withdrawn): The expression vector according to claim 33,

wherein the PPIase having molecular chaperone activity is cyclophilin-type PPIase.

39. (withdrawn): The expression vector according to claim 33,

wherein the PPIase having molecular chaperone activity is parvulin-type PPIase.

40. (canceled): ~~The expression vector according to claim 37,~~

~~wherein the FKBP-type PPIase is archaebacterial FKBP-type PPIase~~.

41. (currently amended): The expression vector according to claim ~~40~~33,

wherein the archaebacterial FKBP-type PPIase is short type FKBP-type PPIase.

42. (previously presented): The expression vector according to claim 33,

wherein the PPIase having molecular chaperone activity comprises an IF domain and/or a C-terminal domain of archaebacterial FKBP-type PPIase.

43. (withdrawn): The expression vector according to claim 37,

wherein the FKBP-type PPIase is trigger factor-type PPIase.

44. (withdrawn): The expression vector according to claim 33,

wherein the PPIase having molecular chaperone activity comprises a N-terminal domain and/or a C-terminal domain of trigger factor-type PPIase.

45. (withdrawn): The expression vector according to claim 37,

wherein the FKBP-type PPIase is FkpA-type PPIase.

46. (withdrawn): The expression vector according to claim 33,

wherein the PPIase having molecular chaperone activity comprises a N-terminal domain of FkpA-type PPIase.

47. (withdrawn): The expression vector according to claim 37,

wherein the FKBP-type PPIase is FKBP52-type PPIase.

48. (withdrawn): The expression vector according to claim 33,

wherein the PPIase having molecular chaperone activity comprises a C-terminal domain of FKBP52-type PPIase.

49. (withdrawn): The expression vector according to claim 38,

wherein the cyclophilin-type PPIase is CyP40-type PPIase.

50. (withdrawn): The expression vector according to claim 33,

wherein the PPIase having molecular chaperone activity comprises a C-terminal domain of CyP40-type PPIase.

51. (withdrawn): The expression vector according to claim 39,

wherein the parvulin-type PPIase is SurA-type PPIase.

52. (withdrawn): The expression vector according to claim 33,

wherein the PPIase having molecular chaperone activity comprises a N-terminal domain of SurA-type PPIase.

53. (previously presented): The expression vector according to claim 36,

wherein the second coding region has a nucleotide sequence encoding a monoclonal antibody.

54. (previously presented): The expression vector according to claim 36,

wherein the second coding region has a nucleotide sequence encoding a membrane protein.

55. (currently amended): A host,

which contains the expression vector according to claim 33, wherein the host is selected from the group consisting of a bacterium, a yeast, a fungus, a plant, an insect cell, and a mammalian cell.

56. (previously presented): The host according to claim 55,

which is Escherichia coli.

57. (withdrawn): A fused protein,

which comprises PPIase having molecular chaperone activity and a desired protein.

58. (withdrawn): The fused protein according to claim 57,

which comprises a protease digestion site between PPIase having molecular chaperone activity and a desired protein.

59. (currently amended): A process for producing a fused protein comprising PPIase having molecular chaperone activity and a desired protein,

comprising culturing a host cell transformed with the expression vector of claim ~~33~~ 36 to express the fused protein.

60. (currently amended): The process for producing a fused protein according to claim 59,

which comprises culturing ~~a host~~the host cell containing the expression vector under conditions suitable for ~~of~~ expression of the expression vector~~, and expressing~~ to produce the fused protein in a cytoplasm of said host cell.

61. (previously presented): The process for producing a fused protein according to claim 59,

which comprises providing a region being transcribed and translated to be a signal sequence at a 5' terminus of the first coding region or a 3' terminus of the second coding region of the expression vector, and culturing a host containing the expression vector under condition of expression of the expression vector to express the fused protein in the periplasm or a medium.

62. (currently amended): ~~The~~ A process for producing a fused protein ~~according to claim 59,~~comprising *in vitro* transcription and translation of

~~which comprises culturing a host cell transformed with~~ the expression vector of claim 36, ~~to express the fused protein~~ in a cell-free translation system using a bacteria extract or a eukaryotic extract.

63. (currently amended): The process for producing a fused protein according to claim 59,

wherein the fused protein is adsorbed on a carrier ~~harboring~~ bound to a macrolide, cyclosporine, juglone, or a compound which inhibits PPIase activity, wherein said carrier is recovered and the fused protein is recovered from the carrier.

64. (currently amended): A process for producing a desired protein,

which comprises digesting ~~the~~ a fused protein comprising ~~the~~ a protease digestion site obtained by the process according to claim 59, with a protease ~~digesting a~~ that digests the protease digestion site.